# Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

> **NCT06143787** · PHASE3 · UNKNOWN · sponsor: **Hyloris Developments** · enrollment: 280 (estimated)

## Conditions studied

- Bleeding From Teeth
- Bleeding Prophylaxis

## Interventions

- **DRUG:** Tranexamic acid

## Key facts

- **NCT ID:** NCT06143787
- **Lead sponsor:** Hyloris Developments
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-07
- **Primary completion:** 2024-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06143787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06143787, "Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06143787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*